Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;51(6):e16349.
doi: 10.1111/jog.16349.

The effect of dolutegravir on obstetrical outcomes among women living with HIV: A retrospective cohort study

Ammar Al Naimi  1   2   3 , Charlotte Chang  1 , Holly Rawizza  1   4 , Oluwaseun Olaifa  5 , Olabanjo Ogunsola  5 , Prosper Okonkwo  5 , Phyllis Kanki  1
Affiliations

The effect of dolutegravir on obstetrical outcomes among women living with HIV: A retrospective cohort study

Ammar Al Naimi et al. J Obstet Gynaecol Res. 2025 Jun.

Abstract

Objective: To assess the effect of dolutegravir (DTG) on obstetrical outcomes for women living with HIV (WLWH).

Methods: This retrospective cohort study evaluated adult WLWH in antenatal care between 2016 and 2022 at two Nigerian centers. Patients were stratified into three antiretroviral therapy (ART) exposure groups: non-DTG ART, DTG-switch, and DTG. Multivariate linear and logistic regression models were utilized to assess the association between the type of ART and gestational weight gain (GWG), small for gestational age (SGA), gestational hypertension, and preterm birth.

Results: The study included 1839 (77.1%) non-DTG users, 359 (15%) DTG users, and 188 (7.9%) DTG switchers. The adjusted association between DTG exposure and GWG was 0.72 (-0.08, 1.53) kg and 0.51 (-0.51, 1.54) kg for the DTG and DTG-switch groups, respectively, compared to other ARTs. The adjusted odds ratios for gestational hypertension were 0.47 (0.09, 2.49) and 1.31 (0.43, 4.02), 0.57 (0.22, 1.52) and 0.73 (0.25, 2.10) for preterm birth, and 0.55 (0.25, 1.20) and 0.26 (0.08, 0.83) for SGA in DTG and DTG-switch, respectively, compared to other ARTs.

Conclusions: DTG therapy is not associated with the risk of gestational hypertension nor preterm birth, and antenatal ART switching to DTG decreases the risk of growth restriction.

Keywords: DTG; HIV; dolutegravir; obstetrical outcomes.

PubMed Disclaimer

Conflict of interest statement

All other authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Mmasa KN, Powis K, Sun S, Makhema J, Mmalane M, Kgole S, et al. Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir‐than with efavirenz‐based antiretroviral therapy. HIV Med. 2021;22(8):715–722. - PMC - PubMed
    1. Meyers K, Qian H, Wu Y, Lao Y, Chen Q, Dong X, et al. Early initiation of ARV during pregnancy to move towards virtual elimination of mother‐to‐child‐transmission of HIV‐1 in Yunnan, China. PLoS One. 2015;10(9):e0138104. - PMC - PubMed
    1. Zhao AV, Crutchley RD, Guduru RC, Ton K, Lam T, Min AC. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV‐1 infection. Retrovirology. 2022;19(1):22. - PMC - PubMed
    1. Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, et al. Dolutegravir in pregnancy as compared with current HIV regimens in the United States. N Engl J Med. 2022;387(9):799–809. - PMC - PubMed
    1. Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, et al. 72 weeks post‐partum follow‐up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN‐2): an open‐label, randomised controlled study. Lancet HIV. 2022;9(8):e534–e543. - PubMed

MeSH terms